{"pmid":32418875,"title":"COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ).","text":["COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ).","Up to one-third of COVID-19 patients admitted to intensive care develop an acute cardiomyopathy, which may represent myocarditis or stress cardiomyopathy. Further, while mortality in older patients with COVID-19 appears related to multi-organ failure complicating acute respiratory distress syndrome (ARDS), the cause of death in younger patients may be related to acute heart failure. Cardiac involvement needs to be considered early on in critically ill COVID-19 patients, and even after the acute respiratory phase is passing. This Statement presents a screening algorithm to better identify COVID-19 patients at risk for severe heart failure and circulatory collapse, while balancing the need to protect health care workers and preserve personal protective equipment (PPE). The significance of serum troponin levels and the role of telemetry and targeted transthoracic echocardiography (TTE) in patient investigation and management are addressed, as are fundamental considerations in the management of acute heart failure in COVID-19 patients.","Heart Lung Circ","Lal, Sean","Hayward, Christopher S","De Pasquale, Carmine","Kaye, David","Javorsky, George","Bergin, Peter","Atherton, John J","Ilton, Marcus K","Weintraub, Robert G","Nair, Priya","Rudas, Mate","Dembo, Lawrence","Doughty, Robert N","Kumarasinghe, Gayathri","Juergens, Craig","Bannon, Paul G","Bart, Nicole K","Chow, Clara K","Lattimore, Jo-Dee","Kritharides, Leonard","Totaro, Richard","Macdonald, Peter S","32418875"],"abstract":["Up to one-third of COVID-19 patients admitted to intensive care develop an acute cardiomyopathy, which may represent myocarditis or stress cardiomyopathy. Further, while mortality in older patients with COVID-19 appears related to multi-organ failure complicating acute respiratory distress syndrome (ARDS), the cause of death in younger patients may be related to acute heart failure. Cardiac involvement needs to be considered early on in critically ill COVID-19 patients, and even after the acute respiratory phase is passing. This Statement presents a screening algorithm to better identify COVID-19 patients at risk for severe heart failure and circulatory collapse, while balancing the need to protect health care workers and preserve personal protective equipment (PPE). The significance of serum troponin levels and the role of telemetry and targeted transthoracic echocardiography (TTE) in patient investigation and management are addressed, as are fundamental considerations in the management of acute heart failure in COVID-19 patients."],"journal":"Heart Lung Circ","authors":["Lal, Sean","Hayward, Christopher S","De Pasquale, Carmine","Kaye, David","Javorsky, George","Bergin, Peter","Atherton, John J","Ilton, Marcus K","Weintraub, Robert G","Nair, Priya","Rudas, Mate","Dembo, Lawrence","Doughty, Robert N","Kumarasinghe, Gayathri","Juergens, Craig","Bannon, Paul G","Bart, Nicole K","Chow, Clara K","Lattimore, Jo-Dee","Kritharides, Leonard","Totaro, Richard","Macdonald, Peter S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418875","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.hlc.2020.04.005","keywords":["acute cardiomyopathy","covid-19","high sensitivity troponin","myocarditis","screening algorithm","targeted transthoracic echocardiogram"],"locations":["New Zealand"],"countries":["New Zealand"],"countries_codes":["NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1667159284390035457,"score":9.490897,"similar":[{"pmid":32418874,"title":"Patients with Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.","text":["Patients with Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.","In the context of the current global COVID-19 pandemic, this Consensus Statement provides current recommendations for patients with, or at risk of developing, genetic heart disease, and for their health care management and service provision in Australia and New Zealand. Apart from general recommendations, there are specific recommendations for the following conditions: cardiomyopathy, Brugada syndrome (including in children), long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). Other recommendations are relevant to patient self-care and primary health care.","Heart Lung Circ","Gray, Belinda","Semsarian, Christopher","Fatkin, Diane","Ingles, Jodie","Atherton, John J","Davis, Andrew M","Sanders, Prashanthan","Pachter, Nicholas","Skinner, Jonathan R","Stiles, Martin K","32418874"],"abstract":["In the context of the current global COVID-19 pandemic, this Consensus Statement provides current recommendations for patients with, or at risk of developing, genetic heart disease, and for their health care management and service provision in Australia and New Zealand. Apart from general recommendations, there are specific recommendations for the following conditions: cardiomyopathy, Brugada syndrome (including in children), long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). Other recommendations are relevant to patient self-care and primary health care."],"journal":"Heart Lung Circ","authors":["Gray, Belinda","Semsarian, Christopher","Fatkin, Diane","Ingles, Jodie","Atherton, John J","Davis, Andrew M","Sanders, Prashanthan","Pachter, Nicholas","Skinner, Jonathan R","Stiles, Martin K"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418874","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.hlc.2020.04.006","keywords":["brugada syndrome","covid-19","cardiomyopathy","catecholaminergic polymorphic ventricular tachycardia","genetic heart disease","long qt syndrome"],"locations":["Australia","New Zealand","Brugada","Australia","New Zealand"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1667159284503281664,"score":296.0956},{"pmid":32360126,"title":"Myocardial injury and COVID-19: Possible mechanisms.","text":["Myocardial injury and COVID-19: Possible mechanisms.","Coronavirus Disease 2019 (COVID-19) has quickly progressed to a global health emergency. Respiratory illness is the major cause of morbidity and mortality in these patients with the disease spectrum ranging from asymptomatic subclinical infection, to severe pneumonia progressing to acute respiratory distress syndrome. There is growing evidence describing pathophysiological resemblance of SARS-CoV-2 infection with other coronavirus infections such as Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus (MERS-CoV). Angiotensin Converting Enzyme-2 receptors play a pivotal role in the pathogenesis of the virus. Disruption of this receptor leads to cardiomyopathy, cardiac dysfunction, and heart failure. Patients with cardiovascular disease are more likely to be infected with SARS-CoV-2 and they are more likely to develop severe symptoms. Hypertension, arrhythmia, cardiomyopathy and coronary heart disease are amongst major cardiovascular disease comorbidities seen in severe cases of COVID-19. There is growing literature exploring cardiac involvement in SARS-CoV-2. Myocardial injury is one of the important pathogenic features of COVID-19. As a surrogate for myocardial injury, multiple studies have shown increased cardiac biomarkers mainly cardiac troponins I and T in the infected patients especially those with severe disease. Myocarditis is depicted as another cause of morbidity amongst COVID-19 patients. The exact mechanisms of how SARS-CoV-2 can cause myocardial injury are not clearly understood. The proposed mechanisms of myocardial injury are direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia.","Life Sci","Babapoor-Farrokhran, Savalan","Gill, Deanna","Walker, Jackson","Rasekhi, Roozbeh Tarighati","Bozorgnia, Behnam","Amanullah, Aman","32360126"],"abstract":["Coronavirus Disease 2019 (COVID-19) has quickly progressed to a global health emergency. Respiratory illness is the major cause of morbidity and mortality in these patients with the disease spectrum ranging from asymptomatic subclinical infection, to severe pneumonia progressing to acute respiratory distress syndrome. There is growing evidence describing pathophysiological resemblance of SARS-CoV-2 infection with other coronavirus infections such as Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus (MERS-CoV). Angiotensin Converting Enzyme-2 receptors play a pivotal role in the pathogenesis of the virus. Disruption of this receptor leads to cardiomyopathy, cardiac dysfunction, and heart failure. Patients with cardiovascular disease are more likely to be infected with SARS-CoV-2 and they are more likely to develop severe symptoms. Hypertension, arrhythmia, cardiomyopathy and coronary heart disease are amongst major cardiovascular disease comorbidities seen in severe cases of COVID-19. There is growing literature exploring cardiac involvement in SARS-CoV-2. Myocardial injury is one of the important pathogenic features of COVID-19. As a surrogate for myocardial injury, multiple studies have shown increased cardiac biomarkers mainly cardiac troponins I and T in the infected patients especially those with severe disease. Myocarditis is depicted as another cause of morbidity amongst COVID-19 patients. The exact mechanisms of how SARS-CoV-2 can cause myocardial injury are not clearly understood. The proposed mechanisms of myocardial injury are direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia."],"journal":"Life Sci","authors":["Babapoor-Farrokhran, Savalan","Gill, Deanna","Walker, Jackson","Rasekhi, Roozbeh Tarighati","Bozorgnia, Behnam","Amanullah, Aman"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360126","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.lfs.2020.117723","keywords":["cardiovascular disease","coronavirus disease 2019","mechanisms of myocardial injury","myocardial injury","myocarditis","severe acute respiratory syndrome coronavirus-2"],"topics":["Mechanism"],"weight":1,"_version_":1666138495507234818,"score":277.65},{"pmid":32363334,"pmcid":"PMC7194983","title":"Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO).","text":["Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO).","COVID-19 has been associated with cardiovascular complications including acute cardiac injury, heart failure and cardiogenic shock. The role of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in the event of COVID-19-associated cardiovascular collapse has not yet been established. We reviewed existing literature surrounding the role of VA-ECMO in the treatment of coronavirus-related cardiovascular collapse. COVID-19 is associated with higher incidence of cardiovascular complications compared to previous coronavirus outbreaks (SARS-CoV, MERS-CoV). We found only one case report from China where COVID-19-associated fulminant myocarditis and cardiogenic shock (CS) was successfully rescued using VA-ECMO as a bridge to recovery (BTR). We identified potential clinical scenarios (cardiac injury, myocardial infarction with and without obstructive coronary artery disease, viral myocarditis, and decompensated heart failure) leading to CS and risk factors for poor/uncertain benefit (age, sepsis, mixed/predominantly vasodilatory shock, prothrombotic state and/or coagulopathy, severe acute respiratory distress syndrome, multi-organ failure or high-risk prognostic scores) specific to using VA-ECMO as BTR in COVID-19 infection. Additional considerations and proposed recommendations specific to the COVID-19 pandemic were formulated with guidance from published data and expert consensus. A small subset of patients with cardiovascular complications from COVID-19 infection may progress to refractory CS. Accepting that resource scarcity may be the overwhelming concern for healthcare systems during this pandemic, VA-ECMO can be considered in highly selected cases of refractory CS and echocardiographic evidence of biventricular failure. The decision to initiate this therapy should take into consideration availability of resources, perceived benefit as well as risks of transmitting disease.","CJC Open","Chow, Justin","Alhussaini, Anhar","Calvillo-Arguelles, Oscar","Billia, Filio","Luk, Adriana","32363334"],"abstract":["COVID-19 has been associated with cardiovascular complications including acute cardiac injury, heart failure and cardiogenic shock. The role of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in the event of COVID-19-associated cardiovascular collapse has not yet been established. We reviewed existing literature surrounding the role of VA-ECMO in the treatment of coronavirus-related cardiovascular collapse. COVID-19 is associated with higher incidence of cardiovascular complications compared to previous coronavirus outbreaks (SARS-CoV, MERS-CoV). We found only one case report from China where COVID-19-associated fulminant myocarditis and cardiogenic shock (CS) was successfully rescued using VA-ECMO as a bridge to recovery (BTR). We identified potential clinical scenarios (cardiac injury, myocardial infarction with and without obstructive coronary artery disease, viral myocarditis, and decompensated heart failure) leading to CS and risk factors for poor/uncertain benefit (age, sepsis, mixed/predominantly vasodilatory shock, prothrombotic state and/or coagulopathy, severe acute respiratory distress syndrome, multi-organ failure or high-risk prognostic scores) specific to using VA-ECMO as BTR in COVID-19 infection. Additional considerations and proposed recommendations specific to the COVID-19 pandemic were formulated with guidance from published data and expert consensus. A small subset of patients with cardiovascular complications from COVID-19 infection may progress to refractory CS. Accepting that resource scarcity may be the overwhelming concern for healthcare systems during this pandemic, VA-ECMO can be considered in highly selected cases of refractory CS and echocardiographic evidence of biventricular failure. The decision to initiate this therapy should take into consideration availability of resources, perceived benefit as well as risks of transmitting disease."],"journal":"CJC Open","authors":["Chow, Justin","Alhussaini, Anhar","Calvillo-Arguelles, Oscar","Billia, Filio","Luk, Adriana"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363334","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cjco.2020.04.003","keywords":["extracorporeal membrane oxygenation","cardiogenic shock","coronavirus","mechanical circulatory support","myocarditis"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138496055640065,"score":266.12387},{"pmid":32503706,"title":"Bedside Focused Cardiac Ultrasound in COVID-19 from the Wuhan Epicenter: The Role of Cardiac Point-of-Care Ultrasound, Limited Transthoracic Echocardiography, and Critical Care Echocardiography.","text":["Bedside Focused Cardiac Ultrasound in COVID-19 from the Wuhan Epicenter: The Role of Cardiac Point-of-Care Ultrasound, Limited Transthoracic Echocardiography, and Critical Care Echocardiography.","BACKGROUND: Three cases of the application of focused cardiac ultrasound in patients with coronavirus disease 2019 are presented. METHODS: Cardiac point-of-care ultrasound, limited transthoracic echocardiography, and critical care echocardiography were applied in cases of heart failure, pulmonary embolism, and myocarditis with thrombus respectively. RESULTS: The impact on patient management and the global context of each presentation are discussed. CONCLUSIONS: Focused cardiac point-of-care ultrasound played an important, front-line role in the bedside management of patients during the COVID-19 pandemic in Wuhan, China.","J Am Soc Echocardiogr","Zhang, Li","Wang, Bin","Zhou, Jianhua","Kirkpatrick, James","Xie, Mingxing","Johri, Amer M","32503706"],"abstract":["BACKGROUND: Three cases of the application of focused cardiac ultrasound in patients with coronavirus disease 2019 are presented. METHODS: Cardiac point-of-care ultrasound, limited transthoracic echocardiography, and critical care echocardiography were applied in cases of heart failure, pulmonary embolism, and myocarditis with thrombus respectively. RESULTS: The impact on patient management and the global context of each presentation are discussed. CONCLUSIONS: Focused cardiac point-of-care ultrasound played an important, front-line role in the bedside management of patients during the COVID-19 pandemic in Wuhan, China."],"journal":"J Am Soc Echocardiogr","authors":["Zhang, Li","Wang, Bin","Zhou, Jianhua","Kirkpatrick, James","Xie, Mingxing","Johri, Amer M"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503706","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.echo.2020.04.004","keywords":["covid-19 infection","critical care echocardiography","focused cardiac ultrasound","limited transthoracic echocardiography","point-of-care ultrasound"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668892488266416128,"score":265.93906},{"pmid":32463543,"title":"Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.","text":["Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.","The Coronavirus Disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and United States. This article is protected by copyright. All rights reserved.","Eur J Heart Fail","Zhang, Yuhui","Stewart Coats, Andrew J","Zheng, Zhe","Adamo, Marianna","Ambrosio, Giuseppe","Anker, Stefan D","Butler, Javed","Xu, Dingli","Mao, Jingyuan","Khan, Muhammad Shahzeb","Bai, Ling","Mebazaa, Alexandre","Ponikowski, Piotr","Tang, Qizhu","Ruschitzka, Frank","Seferovic, Petar","Tschope, Carsten","Zhang, Shuyang","Gao, Chuanyu","Zhou, Shenghua","Senni, Michele","Zhang, Jian","Metra, Marco","32463543"],"abstract":["The Coronavirus Disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and United States. This article is protected by copyright. All rights reserved."],"journal":"Eur J Heart Fail","authors":["Zhang, Yuhui","Stewart Coats, Andrew J","Zheng, Zhe","Adamo, Marianna","Ambrosio, Giuseppe","Anker, Stefan D","Butler, Javed","Xu, Dingli","Mao, Jingyuan","Khan, Muhammad Shahzeb","Bai, Ling","Mebazaa, Alexandre","Ponikowski, Piotr","Tang, Qizhu","Ruschitzka, Frank","Seferovic, Petar","Tschope, Carsten","Zhang, Shuyang","Gao, Chuanyu","Zhou, Shenghua","Senni, Michele","Zhang, Jian","Metra, Marco"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463543","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/ejhf.1915","keywords":["covid-19","coronavirus","diagnosis","heart failure","management","sars-cov2"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1668079521470873600,"score":260.01785}]}